An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.
Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms
DRUG: Bevacizumab
Safety: Incidence of adverse events, up to approximately 1.5 years
Progression-free survival, up to approximately 1.5 years|Overall survival, up to approximately 1.5 years|Overall response rate (complete response + partial response), up to approximately 1.5 years|Clinical benefit rate (complete response + partial response + stable disease), up to approximately 1.5 years
This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.